Jason Greenberg DO

XOMA Royalty Corporation is a biotechnology royalty aggregator that focuses on acquiring economic rights to future milestone and royalty payments related to pre-commercial clinical candidates, fostering innovation in human health. With a growing portfolio of 120 assets, the company provides non-dilutive, non-recourse funding to developers to enable the advancement of internal drug candidates. Operating under a capital-efficient structure and employing a portfolio approach, XOMA mitigates single-asset binary exposure while delivering shareholder value. The company actively seeks to expand its rights to potential milestone and royalty payments associated with therapeutic assets under development by pharmaceutical and biotech firms. Generated from the website